Geneva, Switzerland and Nantes, France, may 23, 2017 – 17 hours 45 – Selexis SA and OSE Immunotherapeutics AG (ISIN : FR0012127173 ; Mnémo : OSE), announced today the signing of a commercial licensing agreement that will give DARE Immunotherapeutics access to cell banks, research Cell Banks) via the platform SUREtechnology Selexis. The implementation of this agreement follows an initial collaboration agreement between the two companies in November 2016, and aims to support the advancement of the clinical development of OSE-127 (Effi-7), receptor antagonist to the interleukin-7, in inflammatory diseases of the intestine such as haemorrhagic rectocolitis.
Download the free guide
Boost your gains
“After a first successful mission on the program of development of OSE-127, we are excited to expand the scope of our collaboration with OSE Immunotherapeutics,” says Marco Bocci, PhD, DPharm, Vice President, Selexis, Licensing and Business Development. “The provision of application technology to a very broad cell lines, and robust allow our partners to be able to collaborate with us on the long-term, to accompany their products throughout the life cycle of their development. We are looking forward to be able to help DARE Immunotherapeutics to realize the potential of his product, OSE-127 “.
“We are very pleased to continue our collaboration with Selexis to realize a key step of our immunotherapy product OSE-127 : the preparation of its clinical stage and its development in ulcerative colitis,” added Dominique Costantini, ceo, OSE Immunotherapeutics.
DARE-127 is a humanized monoclonal antibody that targets the receptor CD127, the alpha chain of the receptor of interleukin-7 (IL-7R). It induces an antagonistic effect powerful resulting in a better control of pathogenic T lymphocytes. This strategy of blocking the IL7 has demonstrated efficacy in several preclinical models to restore the immune balance altered in inflammatory diseases of the bowel such as ulcerative colitis.
ABOUT DARE IMMUNOTHERAPEUTICS
Our ambition is to become one of the world leaders in immunotherapy activation and regulation
DARE Immunotherapeutics) is a biotechnology company specializing in the activation and immune regulation in immuno-oncology, autoimmune diseases and in transplantation.
The company has a balanced portfolio, with a risk profile that is diverse, ranging from the clinical phase to registration of R&D :
Immuno-oncology:
??? Tedopi®, a combination of 10 néoépitopes optimized to induce an activation response in immuno-oncology – ongoing Phase 3 registration in the lung cancer advanced in Europe and the United States, in patients with HLA-A2+ – Status orphan to the United States, Registration as provided for in 2019 – A Phase 2 study of Tedopi® in combination with a checkpoint inhibitor in NSCLC is planned in 2017.
??? DARE-172 (Effi-DEM), checkpoint of the new generation targeting cells of the myeloid suppressor via receptor SIRP-? – In preclinical in several cancer models.
In autoimmune diseases and transplantation :
??? FR104, immunotherapy antagonist of the CD28 – Results of Phase 1 positive – refers to autoimmune diseases, and transplantation – Licensed to Janssen Biotech Inc. for further clinical development.
??? DARE-127 (Effi-7), immunomodulatory receptor antagonist to interleukin-7 – preclinical in inflammatory bowel disease and other autoimmune diseases – Option license agreement with Servier for the development and commercialization of the product.
In the light of medical needs targeted, these products have a real potential blockbuster and make the company the ability to enter into global agreements at different stages of their development with major pharmaceutical players.
DARE Immunotherapeutics seeks the field of immunotherapy, a very attractive market in full expansion. The immunotherapy of cancer may represent to the year 2023, nearly 60% of treatments, compared to less than 3% at the present time* and the market is estimated is estimated to be $ 67 billion by 2018**.
There are more than 80 autoimmune diseases that represent an important market integrating of the major players in the pharmaceutical industry, with sales in excess of 10 billion euros for the main products. The medical need is still largely unfulfilled and will require the provision of new products to control the immune system’s innovative and responsive.
*Citi Research Equity
**BCC Research
More information on http://ose-immuno.com
Download the free guide
Boost your gains
